HomeONCY • NASDAQ
add
Oncolytics Biotech Inc
Previous close
$0.98
Day range
$0.94 - $1.00
Year range
$0.84 - $1.73
Market cap
73.55M USD
Avg Volume
438.63K
P/E ratio
-
Dividend yield
-
Financials
Income Statement
Revenue
Net income
| (CAD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 9.90M | -10.40% |
Net income | -9.54M | 3.85% |
Net profit margin | — | — |
Earnings per share | -0.12 | 10.29% |
EBITDA | -9.86M | 10.56% |
Effective tax rate | -0.13% | — |
Balance Sheet
Total assets
Total liabilities
| (CAD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 19.60M | -50.98% |
Total assets | 24.26M | -47.36% |
Total liabilities | 15.20M | -10.93% |
Total equity | 9.06M | — |
Shares outstanding | 77.07M | — |
Price to book | 8.17 | — |
Return on assets | -87.86% | — |
Return on capital | -167.51% | — |
Cash Flow
Net change in cash
| (CAD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -9.54M | 3.85% |
Cash from operations | -4.83M | 19.87% |
Cash from investing | -32.00K | -100.47% |
Cash from financing | -173.00K | -100.81% |
Net change in cash | -5.25M | -123.38% |
Free cash flow | -1.70M | -171.09% |
About
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
Founded
1998
Headquarters
Website
Employees
29
